Tempus AI, Inc. (TEM) is a publicly traded company in the Healthcare — Medical - Healthcare Information Services industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tes...
Is Tempus AI, Inc. stock overvalued or undervalued in 2026?
As of October 28, 2026, Tempus AI, Inc. (TEM) trades at $67.16 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Tempus AI, Inc.
Market cap $12B · 52 weeks $42 – $90 (15 % below the high) · P/E no earnings · Dividend none · Next earnings November 2, 2026 · expected EPS $-0.09 · Closing price, Oct 28 · accounts published Jul 30.
- Valuation: P/Sales 8.8× (no earnings).
- Business: ROIC −14 % (weak).
- Balance sheet: Net cash/EBITDA 6.1× (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 2 of 4 pass
- Gross margin 62.7 %, fails.
- ROIC −13.9 %, fails.
- R&D / Revenue 25.1 %, passes.
- Net debt / EBITDA −6.1×, passes.
Against its peers (reference peers) — Tempus AI, Inc.: P/E —; EV/EBITDA —; ROIC -13.9 %; $11.9B. Qiagen N.V. (P/E 25.8×; EV/EBITDA 16.0×; ROIC 8.9 %; $10.4B), BillionToOne, Inc. (P/E 184×; EV/EBITDA 99.1×; ROIC 6.3 %; $5.4B), Quest Diagnostics Incorporated (P/E 24.5×; EV/EBITDA 14.2×; ROIC 8.6 %; $27.1B).
Profitability
| Return on Equity | -54.70% |
| Return on Invested Capital | -13.95% |
| Return on Assets | -10.75% |
| Gross Margin | 63.98% |
| Operating Margin | -19.76% |
| Net Margin | -17.77% |
Financial Health
| Debt / Equity | 3.25 |
| Current Ratio | 3.30 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 2.60 |
Price Performance
| 1 month | -7.23% |
| 3 months | +74.63% |
| Year-to-date | +29.74% |
| 1 year | -13.77% |
Related companies: NTRA · ILMN · GH · BLLN · NEO · DGX · QGEN
Explore sector: Healthcare · Medical - Healthcare Information Services
More sections of TEM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks